MF
MCRB icon

Manchester Financial’s Seres Therapeutics MCRB Stock Holding History

Manchester Financial’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-50
Closed -$21K – 402
2021
Q1 		$21K Hold
50
– – 0.01% 317
2020
Q4 		$25K Hold
50
– – 0.02% 248
2020
Q3 		$28K Hold
50
– – 0.02% 193
2020
Q2 		$5K Hold
50
– – ﹤0.01% 386
2020
Q1 		$4K Hold
50
– – ﹤0.01% 380
2019
Q4 		$3K Buy
+50
New +$3.71K ﹤0.01% 474
2019
Q3 		– Sell
-50
Closed -$3K – 279
2019
Q2 		$3K Buy
+50
New +$4.75K ﹤0.01% 421

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Manchester Financial's MCRB Position: Q2 2021 in Review

Manchester Financial sold out of Seres Therapeutics (MCRB) in Q2 2021, closing a stake of 50 shares — an estimated $21K sold.

Manchester Financial first reported a position in MCRB in Q2 2019 and held it in 7 quarters. The position peaked at $28K in Q3 2020. 146 funds tracked by Wall St. Rank hold MCRB as of Q2 2021.

  • Manchester Financial reported no remaining Seres Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Manchester Financial sold 50 Seres Therapeutics shares in Q2 2021, an estimated $21K.
  • Manchester Financial first reported a position in Seres Therapeutics in Q2 2019 and held it in 7 quarters.
  • Manchester Financial's Seres Therapeutics position peaked at $28K in Q3 2020.
  • 146 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2021.

Based on Manchester Financial's 13F filing for Q2 2021, filed 21 Jul 2021.